Search

Xenon Pharmaceuticals Inc

Suletud

SektorTervishoid

39.04 0.51

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

37.86

Max

39.35

Põhinäitajad

By Trading Economics

Sissetulek

-8.4M

-111M

Aktsiakasum

-1.11

Töötajad

358

EBITDA

420K

-111M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+83.17% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

2. nov 2026

Turustatistika

By TradingEconomics

Turukapital

-2.2B

3.8B

Eelmine avamishind

38.53

Eelmine sulgemishind

39.04

Uudiste sentiment

By Acuity

75%

25%

295 / 339 Pingereas Healthcare

Xenon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

22. sept 2026, 20:07 UTC

News

Xenon Pharmaceuticals Inc is advancing slightly higher, following its announcement to present at the TD Cowen Summit on September 23, 2026.

21. sept 2026, 20:06 UTC

News
Social Media

Xenon Pharmaceuticals shares fell amid analyst target cuts, with Baird lowering its target to $90 and Needham reducing it to $60, while enrollment in trials is paused.

18. sept 2026, 23:06 UTC

Xenon Pharmaceuticals Inc is up in after-market trading, buoyed by broader market trends despite ongoing concerns over industrial sector weakness and rising Treasury yields.

17. sept 2026, 23:01 UTC

Social Media
News

Xenon Pharmaceuticals submits a New Drug Application for azetukalner but pauses new patient enrollment in other studies, leading to a significant decline in after-hours trading.

16. sept 2026, 20:10 UTC

Xenon Pharmaceuticals Inc is advancing modestly in Wednesday's market session, despite earlier pulling back from a session high amid a broadly lower market.

15. sept 2026, 20:02 UTC

Xenon Pharmaceuticals shares are lower amid broader market declines linked to a significant drop in the NY Empire State Manufacturing Index for September.

14. sept 2026, 22:01 UTC

Xenon Pharmaceuticals Inc shares are higher in after-market trading, recovering from recent declines despite remaining below the 20-day moving average. No specific news was identified.

11. sept 2026, 20:08 UTC

Xenon Pharmaceuticals Inc shares are lower, marking six consecutive sessions of declines. Broader market sentiment may be affected by a rise in the Consumer Price Index.

9. sept 2026, 20:07 UTC

Xenon Pharmaceuticals Inc. shares are lower today, marking the fourth consecutive session of declines, with no specific news identified for the drop.

8. sept 2026, 20:41 UTC

Xenon Pharmaceuticals Inc shares are lower in after-market hours amid a broader market decline, with no specific company news identified for the drop.

4. sept 2026, 23:40 UTC

Xenon Pharmaceuticals Inc shares are higher in after-market hours, despite no specific company news, amid broader macroeconomic influences.

1. sept 2026, 20:09 UTC

News

Xenon Pharmaceuticals shares are lower as negative sentiment follows an insider sale of 7,068 shares by Chief Medical Officer Kenney Christopher John.

31. aug 2026, 23:31 UTC

Xenon Pharmaceuticals Inc shares are higher in after-market trading, reflecting an upward move since Monday's close amid broader market expectations for interest rate hikes.

28. aug 2026, 20:02 UTC

News

Xenon Pharmaceuticals shares are lower as the company presented Phase 3 data on azetukalner at the European Epilepsy Congress, amid market volatility.

27. aug 2026, 20:02 UTC

Social Media
Event
News

Xenon Pharmaceuticals will present Phase 3 X-TOLE2 trial data at an epilepsy meeting. Shares are lower despite recent announcements regarding upcoming presentations.

26. aug 2026, 21:51 UTC

News

Xenon Pharmaceuticals will present data on azetukalner at the European Epilepsy Congress in September 2026, contributing to shares moving higher in after-market hours.

24. aug 2026, 19:56 UTC

Xenon Pharmaceuticals Inc shares are lower today, reflecting ongoing market weakness. The stock is near the lower end of its one-month range.

21. aug 2026, 23:51 UTC

Xenon Pharmaceuticals shares are lower in after-market trading, reflecting challenges in maintaining upward momentum and positioning below the 20-day moving average.

20. aug 2026, 22:51 UTC

Shares of Xenon Pharmaceuticals are lower in after-market trading, continuing a trend of three consecutive daily declines and trading below the 20-day moving average.

19. aug 2026, 23:01 UTC

Xenon Pharmaceuticals Inc. is higher in after-market trading, rebounding from an initial dip and reflecting strength despite no specific news to explain the movement.

18. aug 2026, 19:26 UTC

Xenon Pharmaceuticals is trading higher today, reflecting cumulative gains since Monday, though it remains below its 20-day moving average.

17. aug 2026, 23:01 UTC

Xenon Pharmaceuticals Inc. is trading higher in after-market hours, despite no specific news to explain the move. The stock remains below its 20-day moving average.

15. aug 2026, 00:01 UTC

Xenon Pharmaceuticals Inc shares are higher in after-market trading, though no specific news was identified to explain the movement.

14. aug 2026, 23:01 UTC

Xenon Pharmaceuticals shares are higher in after-market hours, reflecting a modest gain since Friday's close. The stock remains below its 20-day moving average.

13. aug 2026, 19:16 UTC

Xenon Pharmaceuticals Inc shares are declining, trading below their 20-day moving average amid broader market support, despite rising initial jobless claims.

12. aug 2026, 22:51 UTC

Xenon Pharmaceuticals Inc. shares are lower in after-market trading, reflecting notable volatility and fluctuations since Wednesday's close within the one-month trading range.

11. aug 2026, 23:41 UTC

Xenon Pharmaceuticals Inc shares are lower in after-market trading, continuing a decline since Tuesday's close amid broader market weakness and subdued trading activity.

10. aug 2026, 23:41 UTC

Xenon Pharmaceuticals Inc shares are higher in after-market hours, despite earlier pulling back from a session high. No specific news was identified for the movement.

7. aug 2026, 20:06 UTC

News
Social Media

Xenon Pharmaceuticals shares are lower as RBC cuts the price target to $81.00 and the company reports a larger-than-expected Q2 loss of $110.7 million.

6. aug 2026, 19:36 UTC

Xenon Pharmaceuticals Inc. shares are lower today, retracing earlier gains. The stock is trading near the lower end of its one-month range.

Võrdlus sarnastega

Hinnamuutus

Xenon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

83.17% tõus

12 kuu keskmine prognoos

Keskmine 71.417 USD  83.17%

Kõrge 90 USD

Madal 46 USD

Põhineb 16 Wall Streeti analüütiku instrumendi Xenon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

16 ratings

15

Osta

1

Hoia

0

Müü

Sentiment

By Acuity

295 / 339 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.